SARS-CoV-2-IN-110 (compound Bb1) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-110 exhibits antiviral efficacy against SARS-CoV-2 with an EC50 of 1.10 µM and significantly lower toxicity compared to Lapatinib (HY-50898). SARS-CoV-2-IN-110 inhibits SARS-CoV-2 with a CC50 of > 100 µM, with a selectivity index (SI) of >91[1].
Molecular Weight:
498.94
Formula:
C28H20ClFN4O2
Target:
SARS-CoV
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
